Abstract. 6,9-Disubstituted purines and 7-deazapurines are known to be powerful inhibitors of Mycobacterium tuberculosis (Mtb) in vitro. Analogs modified in the 6-membered ring (imidazopyridines, pyrrolopyridines, benzimidazoles and indoles) were synthesized and evaluated as Mtb inhibitors. The targets were prepared by functionalization on the bicyclic heterocycle or from simple pyridines. The results reported herein, indicate that the purine N-1, but not N-3, is important for binding to the unknown target. The 3-deazapurines appears to be slightly more active compared to the parent purines and slightly less active than their 7-deazapurine isomers. Removal of both the purine N-3 and N-7 did not result in further enhanced antimycobacterial activity but the
toxicity towards mammalian cells was increased. Both 3-deaza and 3,7-dideazapurines exhibited a modest activity against of the Mtb isolate in the state of non-replicating persistence.
Introduction
Tuberculosis (TB) claims approximately 2 million deaths pr. year worldwide and resistance to the drugs in use is a growing problem. Also agents that reduce the duration and complexity of the current therapy would have a major impact on the overall cure rate. 1 We have studied 6,9-disubstituted purines as potent inhibitors of Mycobacterium tuberculosis (Mtb) in vitro, for instance compounds 1a and 1b ( Fig. 1 ). 2 Lately we have examined several classes of non-purine analogs, and identified the 7-deazapurines 1c and 1d as even more active antimycobacterials. 3e These compounds are highly selective towards Mtb compared to other microorganisms, active against several drug resistant strains of Mtb, generally non-toxic towards mammalian cells, and able to affect Mtb inside macrophages. 2, 3 We now report the synthesis and antimycobacterial activities for purine-or 7-deazapurine analogs modified in the 6-membered ring (general structure, see Fig. 1 ).
( Fig. 1) The synthesis of 1-deazapurines 5 is shown in Scheme 1. 2-Chloropyridines 2 4 were reacted with pmethoxybenzylamine to give compounds 3 in high yields. The reaction on the 2,6-dichloropyridine 3b was highly regioselective and only minor amounts of the other possible regioisomer were observed. The nitropyridines 3 were efficiently reduced to diamines 4 and the latter were reacted with triethylorthoformate to give the targets 5.
(Scheme 1)
The 3-deazapurine 7 was readily available by a Stille coupling to introduce the furyl substituent on the previously known structure 6 5 as shown in Scheme 2.
(Scheme 2)
For the chlorinated 3-deazapurine 12 the pyridine 8 6 was chosen as the starting point (Scheme 3).
The amine 8 was N-alkylated with p-methoxybenzyl chloride, and the furyl group was introduced by a highly regioselective Stille coupling, where only formation of a small amount of the difuryl analog was observed. The lasts steps follows those used in the synthesis of the 1-deazapurines 5 (Scheme 1); reduction of the nitro group followed by reaction of the diamine with triethylortoformate to give the bicycle 12. The regioselective outcome of the Stille coupling was determined by NOE spectroscopy on the diamine 11 as shown in Scheme 3.
(Scheme 3)
The bicyclic compounds 13 and 14 were attractive starting materials for the synthesis of the 1,7-dideaza-17 and 3,7-dideazapurines 18, since compounds 13a, 14a, and 14b were commercially available (Scheme 4). Targets 17 and 18 were synthesized by N-alkylation of the pyrrole nitrogen followed by Pd-catalyzed cross coupling to introduce the furyl substituent. The 1,7-dideazapurine 15a was not reactive under conventional Stille coupling conditions, but the target 17a was isolated in an excellent yield when a Suzuki coupling employing the reactive catalyst [(t-Bu) 3 P] 2 Pd was performed. The analog of compound 15b where Y = Cl (structure not shown) was essentially unreactive under both Stille and Suzuki coupling conditions, but the bromide 15b, synthesized by alkylation of 13b, 7 could very easily be converted to the furane 17 by a Stille coupling. The reaction was carried out at ambient temperature to avoid exchange of both halides. The target 18b was synthesized from compound 16b by a Stille coupling. The regioselectivity was complete, and proved by the selective NOE shown in Scheme 4 as well as by HMBC NMR spectroscopy. The conversion was moderate and 33% of the starting material 16b was recovered.
(Scheme 4)
The benzimidazole 22 was synthesized from the commercially available nitrobenzene 19 (Scheme 5). The nitro group was conveniently reduced and the diamine 20 gave the benzimidazole 21 upon reaction with triethylorthoformate, but in contrast to similar reactions on the diaminopyridines 4 (Scheme 1) and 11 (Scheme 3). When the ring forming reaction was performed with triethylorthoformate and acetic acid anhydride, the product 21 was contaminated with ca 20% of the corresponding 3-metylbenzimidazole (structure not shown). Instead the cyclization was carried out in the presence of p-toluenesulfonic acid. 8 Low reactivity of bromobenzimidazoles in Pd-catalyzed cross couplings is reported before, 9 and the final Stille coupling to give the target 22 required a reactive catalyst; [(t-Bu) 3 P] 2 Pd.
(Scheme 5)
Finally the indole 25, formally the 1,3,7-trideaza analog of the purine 1a ( Fig. 1) was synthesized by N-alkylation followed by Stille coupling, from the bromoindole 23. Dialkylation of indoles is not uncommon, 10 and also compound 24b was formed in the alkylation step. Due to the inactivity of the indole 25 as Mtb inhibitor (see below), no attempt was done to improve the outcome of the alkylation reaction.
(Scheme 6)
Biological evaluation
The target compounds 5a, 5b, 7, 12, 17a, 17b, 18a, 18b, 22 and 24 were screened for activity against M. tuberculosis H 37 Rv in the microplate alamar blue assay (MABA) 11 and the MIC values are given in Table 1 . For compounds displaying substantial activity, cytotoxicity towards mammalian cells (VERO cells) was also examined. The values for the previously synthesized purines and deazapurines 1a -d as well as a general structure of the targets, are shown in Fig. 1 .
The 1-deazapurines 5a and 5b and the 1,7-dideazapurines 17a and 17b possessed no significant inhibitory activity against Mtb, indicating that a nitrogen in the purine 1-possition may be important for binding to the (unknown) target. In contrast to earlier findings studying purines, 2 7-deazapurine 3e or pyrimidine 3b,3d analogs as antimycobacterials, it is also interesting to note that this is the first time we observe that a chlorine, in what may be referred to as the 2-position in the parent purine, does not increase the antimycobacterial activity. The 3-deazapurines 7 and 12, on the other hand, where slightly more active than the parent purines (compounds 1a and 1b, respectively),
indicating that the purine N-3 is not involved in binding to target. The toxicity towards mammalian cells (EC 50 VERO cells >128 M) was also low for these compounds. In compounds 18 both the purine N-3 and N-7 is changed with CH. These modifications did not result in an additional improvement of the activity compared to the corresponding 7-deaza-(1c and 1d), but the activity is slightly increased compared to the 3-deazapurines 7 and 12. Furthermore, the toxicity towards VERO cells was increased substantially when the N-7 nitrogen was removed. This is in accordance with what we found when we were comparing purines 1a and 1b with the deazapurines 1c and 1d.
3e
The benzimidazole 22 and the indole 25 did not exhibit significant antimycobacterial activity compared with the most active compounds in this series. The results presented herein and in our recent paper on 7-and 9-deazapurines 3e indicate that the purine N-1 and N-9, but not N-3 and N-7, are important for binding to the elusive target. However, it must be stressed that the changes in antimycobacterial activities observed may also be a result of different uptake or metabolism by the Mtb cells.
A sub-population of the Mtb isolate in a state of non-replicating persistence (NRP). NRP is considered to be an important factor contributing to the long treatment duration (≥6 months required). Hence we investigated if the antimycobacterial purines and non-purine analogs described herein also could affect Mtb in NRP. Compounds 7, 12, and 18 were thus tested in the low-oxygenrecovery assay (LORA) 12 (Table 1) . These substances (except 18b) were all more active in the LORA assay than the purines and 7-deazapurines (MIC LORA >128 M for all compounds 1a-d).
3e Unfortunately the activities found are still quite moderate. The most potent compound in the LORA assay, the 3,7-dideazapurine 18a, is unfortunately exhibiting the highest toxicity towards
VERO cells among the compounds tested for mammalian cytotoxicity.
Compounds 5a, 5b, 7, 12, 17a, 17b, 18a, 18b, 22 and 25 displayed no significant activities against Staphylococcus aureus and Escherichia coli. The MICs for all compounds were >16 g/mL against both bacteria. There was no visible difference in the growth responses of the quality control (QC) strains across the range of dilutions tested. The MIC gentamicin value for the quality control strains of S. aureus and E. coli was 0.5 µg/mL which is within the acceptable specified range. 13 This points towards a selective antimycobacterial mechanism for the 3-deazapurines 7, 12 and 18 as previously found also for purines 2 and 7-deazapurines. 
6-Chloro-4-(furan-2-yl)-N-(4-methoxybenzyl)-3-nitropyridin-2-amine (3b).
A mixture of compound 2b (300 mg, 1.16 mmol), 4-methoxybenzylamine (0.08 mL, 0.6 mmol) and triethylamine (0.08 mL, 0.6 mmol) in DMF (10 mL) was stirred under N 2 at ambient temperature for 24 h and poured in to water (100 mL). The resulting mixture was extracted with EtOAc (2  50 mL), the combined organic extracts were washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo. The residue was diluted with CH 2 Cl 2 (ca. 20 mL) and evaporated with small amount of silica gel. The product was purified by flash chromatography on silica gel eluting with hexane followed by CH 2 Cl 2 -hexane (1:4) and finally CH 2 Cl 2 -hexane (1:2); yield 183 mg (88%), yellow wax. 
5-Chloro-7-(furan-2-yl)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (5b).
A mixture of compound 4b (120 mg, 0.510 mmol) in triethylorthoformate (2.0 mL) and acetic anhydride (2.0 mL) was heated at reflux under N 2 for 1.5 h and evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:4) and finally 
4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine (7).
A mixture of compound 6
(100 mg, 0.370 mmol), Pd(dppf)Cl 2 (15 mg, 0.019 mmol) and 2-furyl(tributyl)tin (0.14 mL, 0.44 mmol) in DMF (4 mL) was stirred at 90 
6-Chloro-4-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine (12). A solution of
compound 11 (70 mg, 0.24 mmol) in triethylorthoformate (2 mL) and Ac 2 O (2 mL) was heated at reflux for 2 h under N 2 and evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane 
4-Chloro-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (15a).
Compound 13a (153 mg, 1.00 mmol) was dissolved in DMF (4.0 mL) and cooled to 0 o C. NaH (ca. 60%, 44 mg, ca. 1.1 mmol) was added and reaction mixture was stirred under N 2 for 1 h before 4-methoxybenzyl chloride (0.14 mL, 1.0 mmol) was added. The resulting mixture was stirred for 19 h and evaporated in vacuo.
Water (40 mL) was added to the residue, which was extracted with EtOAc (2  40 mL). The combined organic layers were washed with brine (40 mL), dried (MgSO 4 ) and evaporated in vacuo.
The product was purified by flash chromatography on silica gel eluting with CH 2 Cl 2 followed by by adding few drops of water. The mixture was poured into water (25 mL) and extracted with EtOAc (2  30 mL). The combined organic layers were dried (MgSO 4 ) and evaporated in vacuo.
The product was purified by flash chromatography on silica gel eluting with hexane followed by was suspended in MeOH (10 mL) and K 2 CO 3 (829 mg, 6.00 mmol) were added followed by 
4,6-Dichloro-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine (16b

4-(Furan-2-yl)-1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (17a)
.
4-Bromo-1-(4-methoxybenzyl)-1H-benzo[d]imidazole (21). p-Toluenesulfonic acid monohydrate
(11 mg, 0.059 mmol) was added to a solution of 20 (120 mg, 0.390 mmol) in triethylorthoformate (4.5 mL) and the resulting mixture was heated at reflux under N 2 for 2 h and excess of triethylorthoformate was removed in vacuo. The product was purified by flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (3:1); yield 110 mg (90%), colorless wax. antimicrobials were determined by the broth microdilution method using cation-adjusted MuellerHinton broth (Oxoid, UK) essentially as previously described. 14 In brief, serial twofold dilutions (16 -0.125 µg/mL) of all samples were prepared in triplicate in microtiter plates and inoculated with a suitably prepared cell suspension to achieve the required start concentration. DMSO was used as solvent and diluent for the test substances, whereas the gentamicin control (used to control the accuracy of testing) was prepared using water as solvent and broth as diluent. Dilution schemes, preparation of the inoculum and incubation conditions were as described in the standard method and in the performance standards supplement. 
4-(Furan
